Vertical: CNMBase Year: 2025
Market Size (2025)
$118.30M
Projected (2032)
$166.30M
CAGR (2022–2032)
5.0%
Key Players
8+
Market Overview
The Global Diclazuril Market was valued at USD 118.30 Million in 2025 and is projected to reach USD 166.30 Million by 2032, registering a CAGR of 4.98% during the forecast period 2026–2032. The market expanded from USD 102.20 Million in 2022 to USD 112.67 Million in 2024 and is expected to add USD 48.00 Million in absolute value between 2025 and 2032.
Diclazuril is a synthetic, non-ionophore anticoccidial of the benzeneacetonitrile (triazinone) class. It is used at very low inclusion rates, typically 1 mg per kg of complete feed, for the prevention of coccidiosis in broiler chickens, growing turkeys and pullets, and as an oral suspension for the prevention of coccidiosis in lambs and calves. It is also used in equine medicine for the treatment of equine protozoal myeloencephalitis. Because diclazuril is a chemical coccidiostat and not an antibiotic, it remains usable in many reduced-antibiotic poultry production programmes, which supports its role in coccidiosis control strategies worldwide.
Key Findings
By livestock, Poultry was the largest segment in 2025 at USD 82.81 Million (70.0% share) and is also the fastest-growing segment, with a CAGR of 5.29% during 2026–2032.
By physical form, Premix accounted for USD 100.56 Million (85.0% share) in 2025 and is the fastest-growing form, with a CAGR of 5.14%.
Asia Pacific was the leading region in 2025 with USD 49.69 Million (42.0% share). Middle East & Africa is the fastest-growing region, with a CAGR of 5.95%.
China was the leading country in 2025 at USD 22.86 Million, while India is the fastest-growing country, with a CAGR of 7.07% during 2026–2032.
North America and Latin America each accounted for USD 21.29 Million in 2025; Latin America is projected to grow faster, at a CAGR of 5.23% against 4.24% for North America.
Segmentation Summary
The market is analysed by livestock (Poultry and Others), by physical form (Premix and Others) and by region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), with country-level analysis within each region. Poultry dominates demand because diclazuril is primarily administered continuously through broiler and turkey feed, whereas the Others livestock segment, which covers ruminants (lambs and calves), rabbits, horses and other species, relies on oral suspensions, pellets and smaller-volume formulations. Premix is the dominant physical form because the in-feed route is the standard method of delivering coccidiostats to commercial flocks through feed mills.
Competitive Landscape Summary
The market is moderately consolidated at the branded finished-product level and fragmented at the active pharmaceutical ingredient (API) level. Elanco Animal Health, through the Clinacox brand, and Huvepharma, through Coxiril, are the principal suppliers of in-feed diclazuril premixes. Merck Animal Health (MSD Animal Health) holds the Vecoxan oral suspension for lambs and calves and the Protazil pellets for horses. Generic oral suspensions from Chanelle Pharma, Bimeda and Viyash Scientific (through Laboratorios Karizoo) have broadened competition in the ruminant segment in Europe, while Chinese API producers such as Guobang Pharma and Apeloa Pharmaceutical supply diclazuril API to formulators. Recent activity centres on regulatory renewals, species extensions, combination products and generic registrations rather than on large-scale capacity additions.
Challenges and Opportunities
The main challenges are the development of Eimeria resistance to diclazuril under continuous use, competition from ionophores, other chemical anticoccidials and live coccidiosis vaccines, and regulatory requirements for resistance monitoring and environmental assessment that raise the cost of maintaining authorisations. Price pressure from generic API supply also limits value growth in several markets.
Opportunities arise from rising poultry meat production in Asia Pacific, Latin America and Middle East & Africa, from the continued use of non-antibiotic chemical coccidiostats in reduced-antibiotic production systems, from combination products such as narasin with diclazuril, and from the growth of ruminant coccidiosis prevention in intensive calf and lamb rearing.
Future Outlook
The market is expected to grow steadily, rising from USD 124.21 Million in 2026 to USD 166.30 Million by 2032. Growth will be led by Asia Pacific, which is projected to reach USD 72.04 Million by 2032, and by high-growth countries such as India, Saudi Arabia, UAE and Mexico. Product stewardship through rotation and shuttle programmes will be central to preserving the efficacy of diclazuril, and suppliers that combine regulatory depth, broad species claims and reliable API sourcing are expected to strengthen their positions.
The Diclazuril Market market is projected to grow at a CAGR of 5.0% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Diclazuril, chemically 2,6-dichloro-α-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3H)-yl)benzeneacetonitrile, is a synthetic antiprotozoal compound of the benzeneacetonitrile (triazinone) group. It acts against the intracellular developmental stages of Eimeria species, interrupting both the asexual and sexual phases of the parasite life cycle. It is used for the prevention of coccidiosis in poultry, lambs and calves, for the prevention of coccidiosis in rabbits, and for the treatment of equine protozoal myeloencephalitis caused by Sarcocystis neurona.
For the purpose of this study, the Global Diclazuril Market includes the value of diclazuril-based products sold for animal use, covering in-feed premixes and microgranulated preparations, oral suspensions, oral solutions, pellets and other finished formulations, as well as diclazuril combinations in which diclazuril is an active component. The market excludes other anticoccidial actives used alone, such as toltrazuril, ionophores (monensin, salinomycin, narasin, maduramicin, lasalocid and semduramicin), nicarbazin, robenidine and decoquinate, as well as live coccidiosis vaccines and phytogenic feed additives, which are treated as substitutes. Human pharmaceutical use is not included.
Scope of the Study
Segmentation by Livestock: Poultry and Others.
Segmentation by Physical Form: Premix and Others.
Segmentation by Region: North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Country coverage: U.S., Canada and Mexico (North America); Germany, U.K., France, Italy, Spain and Rest of Europe (Europe); China, India, Japan and Rest of Asia Pacific (Asia Pacific); Brazil, Argentina and Rest of Latin America (Latin America); UAE, Saudi Arabia, South Africa and Rest of MEA (Middle East & Africa).
Timeline: historic years 2022–2024, base year 2025 and forecast period 2026–2032.
Currency: all values are presented in USD Million.
Research Objectives
To estimate the size of the global diclazuril market in value terms for 2022–2025 and to forecast it for 2026–2032.
To analyse the market by livestock and by physical form and identify the largest and fastest-growing segments.
To assess regional and country-level demand for diclazuril, linked to poultry and ruminant production patterns.
To examine the drivers, restraints, opportunities and challenges affecting diclazuril use, including anticoccidial resistance and reduced-antibiotic production programmes.
To review the regulatory framework governing diclazuril as a feed additive and veterinary medicine, including authorisations and maximum residue limits.
To evaluate the value chain from API synthesis to premix manufacturing, distribution and end use on farms.
To profile the competitive environment, including the positioning of leading suppliers and key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured process consisting of data mining, market definition, secondary research, primary validation, market size estimation, data triangulation and forecasting. Market boundaries were first fixed around diclazuril-based products for animal use. Product approvals, registered formulations and species claims were then mapped by region to identify where diclazuril is legally marketed and how it is used. Market values were built up from livestock population and production data, anticoccidial usage patterns and price points, and were cross-checked against supplier-side information before the forecast was developed.
Secondary Research
Secondary research covered the following source types, selected for their relevance to veterinary anticoccidials and poultry production:
Regulatory and government bodies: the U.S. Food and Drug Administration Center for Veterinary Medicine, the European Commission feed additive register, the European Food Safety Authority, the European Medicines Agency and Union Product Database, Health Canada, China's Ministry of Agriculture and Rural Affairs, and national veterinary medicine regulators.
Agricultural statistics: USDA Foreign Agricultural Service livestock and poultry reports, FAOSTAT and national livestock census data for poultry, cattle and sheep populations.
International standard-setting bodies: Codex Alimentarius and Joint FAO/WHO Expert Committee on Food Additives (JECFA) evaluations of veterinary drug residues, and the World Organisation for Animal Health.
Industry associations: national poultry and feed manufacturers' associations and animal health industry federations.
Company sources: annual reports, financial results, product labels, summaries of product characteristics and press releases of animal health companies and API manufacturers.
Trade and scientific journals: poultry science, veterinary parasitology and feed industry publications covering coccidiosis control, anticoccidial resistance and feed additive markets.
Paid databases: trade, pharmaceutical API supplier and company financial databases.
Primary Research
Primary research was used to validate secondary findings, refine segment splits and test forecast assumptions. Discussions were held with participants on both the supply side and the demand side of the market.
Supply side: API manufacturers, animal health companies, premix manufacturers, product managers for anticoccidials, regulatory affairs specialists and distributors of veterinary products.
Demand side: poultry integrators, nutritionists, feed mill managers, poultry and ruminant veterinarians, large livestock farm operators and veterinary practitioners treating equine cases.
Objectives: to confirm usage patterns of diclazuril within shuttle and rotation programmes, to understand pricing and procurement practices, to assess the impact of resistance and vaccine uptake, and to validate regional demand trends and growth expectations.
Market Size Estimation
Bottom-up approach: country-level demand was estimated from poultry placements and meat production, the share of flocks receiving anticoccidials, the share of programmes using diclazuril and the typical inclusion rate, together with the number of calves and lambs treated with oral suspensions and average selling prices. Country values were aggregated to obtain regional and global totals.
Top-down approach: the global anticoccidial market was used as a reference, and the share attributable to diclazuril was derived from supplier revenues, product portfolios and regional usage patterns. This was then allocated to regions and segments.
Data triangulation: results from the two approaches were compared and reconciled with supply-side information, including API supply capacity and finished-product availability, to arrive at final market estimates.
Forecasting Methodology
Forecasts for 2026–2032 were developed by projecting the base-year value forward on the basis of factors including poultry and ruminant production growth, feed production trends, regulatory changes affecting anticoccidial use, adoption of reduced-antibiotic production systems, uptake of coccidiosis vaccines, development of resistance, generic competition and price trends. Each factor was weighted according to its expected influence in each region, and the resulting growth rates were reviewed against expert input.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024.
Base year: 2025.
Forecast period: 2026–2032.
Currency: USD Million.
Assumptions and Limitations
Regulatory authorisations for diclazuril in major markets are assumed to remain in force through the forecast period, subject to routine renewal.
No major disease outbreak or trade disruption is assumed to cause a sustained decline in global poultry production.
Currency values are expressed in constant USD and do not account for exchange rate fluctuations.
Selling prices are assumed to follow historical trends, with moderate price pressure from generic supply.
Company-level data for privately held suppliers are limited, which restricts the precision of supply-side cross-checks.
Country-level data for "Rest of" groupings are estimated on an aggregated basis.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Diclazuril Market is moderately consolidated at the finished-product level and fragmented at the API level. The in-feed premix segment, which accounted for 85.0% of the market in 2025, is led by a small number of companies with authorised feed additive and medicated feed products, principally Elanco Animal Health and Huvepharma. The oral suspension segment for lambs and calves is more fragmented, with the originator brand held by Merck Animal Health competing against several generics. Upstream, diclazuril API is supplied by a number of producers in China and India.
Competition is based on regulatory coverage across countries and species, product quality and homogeneity, technical service to integrators and veterinarians, positioning within rotation and shuttle programmes, and price. The ability to maintain authorisations through periodic renewals, which now require resistance monitoring in the European Union, is an important differentiator. Recent strategic activity has focused on product renewals, combination products, species extensions, generic registrations and portfolio reshaping through acquisitions and divestments.
Key Player Positioning
Leaders: Elanco Animal Health and Merck Animal Health are the leading players. Elanco, which reported revenue of USD 4,715 million for FY2025, holds the Clinacox brand in the U.S., Canada and Europe and recently secured the renewal of Clinacox 0.5% and the authorisation of the narasin–diclazuril combination Interban in the European Union. Merck Animal Health, whose animal health sales reached USD 6,354 million in FY2025, owns the Vecoxan brand for lambs and calves, acquired from Elanco in 2020, and the Protazil equine product in the U.S.
Challengers: Huvepharma is the main challenger in in-feed diclazuril through Coxiril, which carries authorisations for chickens, turkeys, guinea fowl, pheasants, pullets and rabbits in the European Union, and has added the Cocciril oral suspension. Viyash Scientific (formerly SeQuent Scientific), which reported consolidated revenue of INR 34,203 million for FY2026, combines diclazuril API production with finished products through Laboratorios Karizoo.
Niche players: Chanelle Pharma and Bimeda compete in generic diclazuril oral suspensions for sheep and cattle in Europe, with Bimeda also active in Africa. Guobang Pharma, which reported revenue of RMB 6,011 million for 2025, and Apeloa Pharmaceutical, which reported revenue of RMB 9,784 million for 2025, are API suppliers serving formulators globally.
Competitor Dashboard
The table below presents a qualitative assessment of the profiled companies across four parameters.
Threat of New Entrants: Medium
Product authorisations for feed additives and veterinary medicines require extensive safety, efficacy and residue data and periodic renewal, creating a significant barrier.
Generic entry is possible once data protection periods expire, as shown by the number of generic oral suspensions authorised in Europe since 2024.
Readily available API from Asian producers lowers the technical barrier for formulators with regulatory capabilities.
Bargaining Power of Suppliers: Medium
API supply is concentrated among a limited number of producers in China and India.
Several qualified API sources exist, and large animal health companies can switch or dual-source.
Environmental and regulatory actions affecting chemical plants in China can temporarily tighten supply.
Bargaining Power of Buyers: High
Large integrators and feed mills purchase in volume and negotiate prices across their full anticoccidial programmes.
Buyers can rotate among many alternative anticoccidials and vaccines, which strengthens their negotiating position.
Cost per tonne of feed is a key purchasing criterion in low-margin broiler production.
Threat of Substitutes: High
Ionophores, other chemical anticoccidials and toltrazuril are effective alternatives for coccidiosis control.
Live coccidiosis vaccines are increasingly used, particularly in reduced-antibiotic programmes.
Phytogenic and other natural feed additives are promoted as supportive options.
Intensity of Competitive Rivalry: Medium
A small number of branded suppliers dominate in-feed premixes, which moderates rivalry in the core poultry segment.
Rivalry is stronger in ruminant oral suspensions, where several generics compete with the originator brand.
Competition is based on price, technical service, regulatory coverage and positioning within rotation programmes.
Threat of New Entrants: Medium; Regulatory barriers offset by generic entry and accessible API.
Bargaining Power of Suppliers: Medium; Concentrated but multi-source API supply.
Bargaining Power of Buyers: High; Large integrators with many alternatives.
Threat of Substitutes: High; Ionophores, other chemicals, vaccines and phytogenics.
Intensity of Competitive Rivalry: Medium; Few premix suppliers; more generics in ruminant products.
Market estimates by geography (2032)
InsightAsia Pacific leads with $72.04M by 2032, while Middle East & Africa is projected to grow fastest at a 6.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $18.79M | $23.09M | $28.44M | 4.2% | 17% |
| Europe | $15.85M | $19.06M | $22.95M | 3.8% | 14% |
| Asia Pacific | $42.35M | $55.32M | $72.04M | 5.5% | 43% |
| Latin America | $18.26M | $23.60M | $30.43M | 5.2% | 18% |
| Middle East & Africa | $6.95M | $9.32M | $12.44M | 6.0% | 7% |
| Total | $102.20M | $130.40M | $166.30M | 5.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$166.30M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Poultry | $118.91M | 5.3% | 71% |
| Others | $47.40M | 4.2% | 29% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Diclazuril Market covering market dynamics, competitive landscape, and strategic outlook.
The Diclazuril Market market is projected to reach $166.30M by 2032, growing at 5.0% CAGR. The Poultry segment holds the largest share.
Demand for diclazuril is linked closely to the scale of commercial poultry production and to the way coccidiosis control programmes are designed. Coccidiosis is one of the most economically significant diseases in poultry; a study by Blake et al. (2020) estimated its global cost to the chicken industry at about GBP 10.4 billion per year at 2016 prices. Against this background, the market is shaped by growth in poultry meat output, policies that limit antibiotic use in food animals, the relative position of chemical anticoccidials, ionophores and vaccines in control programmes, and the need to manage parasite resistance.
Market Growth Factor Analysis
The table below summarises the macro and micro factors that influence the Global Diclazuril Market and the expected strength of their impact over three time periods. The impact scores are analyst assessments on a scale of 1 to 10, where a higher score indicates a stronger influence on the market.
Expansion of Global Poultry Meat Production
Poultry is the largest and fastest-growing source of meat globally, and coccidiosis prevention is a standard part of commercial broiler production. According to the USDA Foreign Agricultural Service, world chicken meat production rose from 104.4 million tonnes in 2024 to 108.0 million tonnes in 2025, with a further increase forecast for 2026. The largest producers, the U.S., China, Brazil and the European Union, all operate intensive broiler systems in which birds are reared at high densities on litter, conditions that favour the build-up of Eimeria oocysts. Each additional flock placed requires an anticoccidial programme from day one, so growth in placements translates directly into demand for in-feed coccidiostats. Production growth is particularly strong in Brazil, India, Southeast Asia and the Gulf states, where integrators are expanding capacity to meet rising domestic consumption and export demand. Because diclazuril is effective at very low inclusion rates and is suited to use in starter and grower feeds, it benefits from this expansion both as a stand-alone programme and as one component of shuttle programmes.
Restrictions on Antibiotic Use in Food Animals
Regulatory and market pressure to reduce antibiotic use in livestock supports demand for non-antibiotic coccidiostats. China's Ministry of Agriculture and Rural Affairs withdrew growth-promoting drug feed additives from 1 January 2020 under Announcement No. 194, while allowing anticoccidials to remain in use under veterinary drug approval numbers. In the United States, poultry raised under "No Antibiotics Ever" (NAE) programmes cannot receive ionophores, because ionophores are classified as antibiotics, but they may receive synthetic chemical anticoccidials such as diclazuril. Elanco markets Clinacox as a non-antibiotic feed additive with no withdrawal period when used according to the label. Where integrators and retailers adopt reduced-antibiotic standards, chemical coccidiostats and vaccines take on a larger role in coccidiosis control, which sustains the use of diclazuril in both conventional and reduced-antibiotic production.
High Economic Burden of Coccidiosis
Coccidiosis causes losses through mortality, reduced weight gain, poorer feed conversion and increased susceptibility to secondary conditions such as necrotic enteritis. Subclinical coccidiosis is often more costly than clinical outbreaks because it affects performance across entire flocks without obvious signs. The estimate by Blake et al. (2020) of about GBP 10.4 billion per year, equivalent to roughly GBP 0.16 per chicken produced, illustrates the scale of the problem. Since feed accounts for the largest share of broiler production costs, even small improvements in feed conversion justify the cost of prevention. Diclazuril's low dose rate and activity against several economically important Eimeria species make it a cost-effective option within these programmes, which encourages its continued use by integrators that measure returns on a cost-per-kilogram basis.
Intensification of Calf and Lamb Rearing
Coccidiosis is also an important cause of diarrhoea and reduced growth in young ruminants, particularly in housed calves and in lambs reared intensively. Diclazuril oral suspensions at 2.5 mg/ml, such as Vecoxan, Dycoxan, Bimacox, Cocciril and Diclacare, are authorised in Europe for the prevention of clinical signs of coccidiosis in lambs and calves. Larger herd sizes, greater use of group housing and stronger focus on young-stock performance in dairy and beef systems are increasing the use of strategic, single-dose metaphylactic treatments. The recent authorisation of several generic diclazuril suspensions in European markets since 2024 has also improved product availability and price accessibility, supporting growth in the Others livestock segment.
Growth in Emerging Poultry Markets
Asia Pacific, Latin America and Middle East & Africa offer the strongest growth potential as integrators expand broiler capacity and adopt structured coccidiosis control programmes. India, Saudi Arabia, UAE and Mexico are among the fastest-growing countries in this market, with CAGRs of 7.07%, 6.60%, 6.43% and 6.28% respectively during 2026–2032. Suppliers with local registration, technical service and distribution capabilities in these markets can capture a large share of incremental demand.
Combination Products and Species Extensions
Combination products and extended species claims open additional uses for diclazuril. In September 2026, the European Union authorised Interban, a preparation of narasin and diclazuril, for broilers and pullets. Coxiril's authorisation was extended in December 2023 to chickens reared for laying and to pheasants, and it is also authorised for rabbits. Such extensions allow diclazuril to be used across more production types and support value growth beyond the core broiler segment.
Expansion of Ruminant and Equine Applications
Wider adoption of coccidiosis prevention in calves and lambs, particularly in regions where dairy and small-ruminant production is intensifying, provides a growth avenue for oral suspensions. In equine medicine, Merck Animal Health has supported Protazil with research; in September 2025 the company announced a pharmacokinetic study showing that diclazuril concentrations in cerebrospinal fluid exceeded the minimum inhibitory concentration for Sarcocystis neurona within 12 hours in healthy horses. Continued investment in such evidence may strengthen diclazuril's position in niche, higher-value applications.
Development of Resistance in Eimeria
Chemical anticoccidials, including diclazuril, are generally more prone to resistance development than ionophores when used continuously. Field studies have reported diclazuril resistance in Eimeria isolates; for example, a study published in Frontiers in Veterinary Science in January 2026 found field isolates from Sichuan, China, to be resistant to diclazuril. Recognising this risk, recent European authorisations for diclazuril products require post-market monitoring of Eimeria resistance. Resistance limits the number of consecutive cycles in which diclazuril can be used on a farm and encourages rotation with other products, which constrains volume growth.
Competition from Vaccines and Alternative Anticoccidials
Live coccidiosis vaccines are increasingly used, especially in breeders, layers and reduced-antibiotic broiler production, and they can replace in-feed anticoccidials for part of the year in rotation programmes. Diclazuril also competes with ionophores, other chemical coccidiostats such as nicarbazin, robenidine and decoquinate, and with phytogenic products. In the U.S., some integrators have moved from NAE to "No Antibiotics Important to Human Medicine" standards, which allows ionophores to be used again and may reduce reliance on chemical products in those programmes.
Regulatory and Renewal Costs
Feed additive and veterinary medicine authorisations must be periodically renewed and are subject to updated safety, efficacy, residue and environmental assessments. In its 2024 opinion on the renewal of Clinacox 0.5%, EFSA could not conclude on the environmental safety of the additive. Such requirements raise the cost of maintaining authorisations and can discourage smaller suppliers from entering or remaining in certain markets.
Wider Use of Rotation and Shuttle Programmes
To preserve product efficacy, producers increasingly alternate between ionophores, chemical anticoccidials and vaccines across production cycles, or use shuttle programmes in which different products are used in starter and grower feeds. Diclazuril is commonly positioned as the chemical component of these programmes. This trend supports stable long-term demand but limits continuous use of any single product.
Growth of Generic Products
Generic diclazuril products have multiplied in Europe, particularly oral suspensions for lambs and calves authorised through decentralised procedures, such as Bimacox (2024), Diclacare (2025) and Cocciril (2026 in Finland). Generic competition improves accessibility but puts pressure on prices for established brands.
Concentration of API Supply in Asia
A large share of diclazuril API is manufactured in China and India by companies such as Guobang Pharma, Apeloa Pharmaceutical and Viyash Scientific. This concentration supports competitive pricing but exposes formulators to supply chain risks related to environmental inspections, trade measures and logistics disruption. Some formulators are responding by qualifying multiple API sources.
Stricter Stewardship and Monitoring Requirements
Regulators are attaching stewardship conditions to authorisations. The renewed EU authorisation of Clinacox 0.5% under Regulation (EU) 2026/2086 and the extended authorisation of Coxiril under Regulation (EU) 2023/2733 both include requirements for monitoring Eimeria resistance. Suppliers are expected to invest more in field surveillance and technical support to maintain product positioning.
The diclazuril value chain comprises four main stages, from chemical inputs to the farms where the product is used.
Raw materials and API synthesis: Diclazuril is produced through multi-step organic synthesis from chlorinated aromatic intermediates and triazine-forming reagents. API manufacture is concentrated in China and India, where producers operate under veterinary GMP and supply international customers supported by Veterinary Master Files and Certificates of Suitability. API cost, purity and impurity profile are key competitive factors at this stage.
Formulation and manufacturing: Animal health companies convert the API into finished products, mainly 0.2% or 0.5% premixes and microgranulated preparations on carriers such as wheat flour or calcium carbonate, as well as 2.5 mg/ml oral suspensions and equine pellets. This stage requires regulatory dossiers, product-specific authorisations and quality control to ensure homogeneity at very low inclusion rates.
Distribution and channels: Premixes are supplied directly to integrators and commercial feed mills, or through premix and feed additive distributors, and are incorporated into complete feed. Oral suspensions and equine products are distributed through veterinary wholesalers, veterinary practices and licensed retailers, often requiring a prescription.
End users: End users are broiler and turkey integrators, pullet rearers, game bird producers, rabbit farms, dairy and beef farms rearing calves, sheep farms and equine owners and veterinarians. Integrators and large feed producers are the dominant buyers by volume.
United States: Diclazuril for poultry feed is regulated by the FDA Center for Veterinary Medicine. Clinacox (NADA 140-951) is approved as a 0.2% Type A medicated article for broiler chickens and growing turkeys, with conditions of use set out in 21 CFR 558.205. Tolerances for residues in chicken and turkey tissues are established in 21 CFR 556.185. Protazil 1.56% pellets for horses are approved under NADA 141-268 and codified in 21 CFR 520.606.
Canada: Veterinary drugs are regulated by Health Canada's Veterinary Drugs Directorate. Clinacox 0.5% Premix is authorised for broiler chickens and growing turkeys under a Drug Identification Number.
European Union: In-feed diclazuril is authorised as a feed additive in the category "coccidiostats and histomonostats" under Regulation (EC) No 1831/2003. Current product authorisations include Clinacox 0.5%, renewed by Commission Implementing Regulation (EU) 2026/2086; Coxiril, authorised under Regulations (EU) 2015/46, (EU) 2015/1417 and (EU) 2023/2733; and Interban (narasin and diclazuril), authorised by Regulation (EU) 2026/2061. Oral suspensions for lambs and calves are veterinary medicinal products governed by Regulation (EU) 2019/6. Maximum residue limits are set in Regulation (EU) No 37/2010.
United Kingdom: The Veterinary Medicines Directorate authorises veterinary medicines such as diclazuril oral suspensions, while the Food Standards Agency maintains the register of authorised feed additives under assimilated law.
China: The Ministry of Agriculture and Rural Affairs regulates veterinary drugs and feed additives. Under Announcement No. 194 (2019), growth-promoting drug feed additives were withdrawn from 2020, while anticoccidials were permitted to continue in use under veterinary drug approval numbers.
International standards: The Joint FAO/WHO Expert Committee on Food Additives established an acceptable daily intake for diclazuril of 0–0.03 mg/kg body weight and recommended maximum residue limits for poultry, sheep and rabbit tissues, which inform Codex Alimentarius standards used by many importing countries.
Other regions: In India, veterinary drugs are regulated under the Drugs and Cosmetics Act, 1940. In Brazil, veterinary products require registration with the Ministry of Agriculture and Livestock (MAPA). In South Africa, stock remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).
The table below lists key developments by the profiled companies from 2022 onward.
Aug 2022: Bimeda; Acquisition; Acquired Afrivet, a South African animal health company, expanding its presence in Africa.
2022: Huvepharma; Expansion; Established an affiliate in South Korea and a representative office in Ukraine.
2023: Huvepharma; Expansion; Established affiliates in Indonesia and the Philippines.
Dec 2023: Huvepharma; Regulatory Approval; Regulation (EU) 2023/2733 extended the authorisation of Coxiril (diclazuril) to chickens reared for laying and pheasants.
Feb 2024: Chanelle Pharma; Acquisition; Agreement for Chanelle Pharma, maker of Dycoxan and Diacox diclazuril suspensions, to be acquired by Exponent Private Equity.
Jul 2024: Elanco Animal Health / Merck Animal Health; Divestment / Acquisition; Merck Animal Health completed the acquisition of Elanco's aqua business for about USD 1.3 billion, as Elanco refocused on core segments.
Jul 2024: Bimeda; Product Approval; Bimacox 2.5 mg/ml diclazuril oral suspension authorised in Portugal, followed by Austria in November 2024.
Aug 2024: Elanco Animal Health; Regulatory; EFSA published its opinion on the renewal of Clinacox 0.5%, confirming safety for target animals and consumers and efficacy at 1 mg/kg feed.
Sep 2024: Huvepharma; Divestment; Olon S.p.A. acquired Huvepharma Italia.
Mar 2025: Viyash Scientific (Karizoo); Product Approval; Diclacare 2.5 mg/ml diclazuril oral suspension authorised in the U.K., followed by Spain in April 2025.
2025: Huvepharma; Expansion; Established an affiliate in Malaysia.
Sep 2025: Merck Animal Health; Research; Announced a pharmacokinetic study confirming rapid cerebrospinal fluid penetration of Protazil (diclazuril) in horses.
Dec 2025: Viyash Scientific; Merger; Amalgamation of SeQuent Scientific and Viyash took effect, creating Viyash Scientific.
Mar 2026: Huvepharma; Product Approval; Cocciril 2.5 mg/ml diclazuril oral suspension authorised in Finland.
Mar 2026: Guobang Pharma; Investment; Announced a RMB 1.02 billion upgrade project for APIs and intermediates.
Sep 2026: Elanco Animal Health; Regulatory Approval; Regulation (EU) 2026/2061 authorised Interban (narasin and diclazuril) for broilers and pullets until October 2036.
Sep 2026: Elanco Animal Health; Regulatory Renewal; Regulation (EU) 2026/2086 renewed the authorisation of Clinacox 0.5% for broilers and chickens reared for laying until October 2036.
Political
Government policies to reduce antimicrobial use in livestock favour non-antibiotic coccidiostats.
Trade policies and tariffs affect the flow of API from China and India to formulators in other regions.
Food security programmes in Asia and the Middle East support domestic poultry expansion.
Economic
Feed costs and broiler margins influence spending on prevention programmes.
Rising incomes in emerging economies increase per capita poultry consumption.
Price competition from generic products affects average selling prices.
Social
Consumer interest in reduced-antibiotic meat shapes integrators' choice of anticoccidials.
Animal welfare expectations encourage effective prevention of enteric disease.
Poultry is widely accepted across religious and cultural groups, supporting broad demand.
Technological
Microgranulated premixes improve dust control and homogeneity at low inclusion rates.
Molecular tools and anticoccidial sensitivity tests support resistance monitoring.
Advances in live and recombinant vaccines create competing control options.
Environmental
Environmental risk assessments of diclazuril excreted in manure form part of regulatory renewals.
Environmental controls on chemical manufacturing in China affect API production.
Good litter management reduces oocyst load and complements anticoccidial use.
Legal
Periodic renewal of feed additive authorisations requires updated data packages.
Maximum residue limits and withdrawal periods govern use in food-producing animals.
Data protection and generic authorisation rules influence the timing of competitive entry.
Profiles of 31 companies operating in the Diclazuril Market market, including revenue, employee count, and market positioning where available.
Showing 31 of 31 companies
Chanelle Pharma — Healthcare
3 interactive charts drawn from the Diclazuril Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Diclazuril Market By Physical Form
Global Diclazuril Market By Livestock
Global Diclazuril Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
